RVTY

TentativeAI MemoPost-earnings T+3

Revvity

As of 2026-08-07/Post-earnings T+3/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-07 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

high-coverage report lacks a dated company-specific catalyst beyond generic cadence; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Action

—

Confidence

high

Horizon

—

Key catalyst

Q2 2026 beat and raised FY26 outlook • 2026-08-04

Base target: $121 / p=50% prob

Biggest risk

Life Sciences pro forma organic revenue declined 3%, and Q2 adjusted EPS included approximately $0.11 from tariff refunds. The China IDX divestiture removes a roughly 6% revenue contributor and remains subject to closing conditions and regulatory approvals. No verified post-print analyst target or estimate revisions were identified.

Invalidation

Break below $100 or thesis failure.

What would change my mind?

The Q2 result showed stronger diagnostics demand, adjusted margin expansion, and a raised FY26 pro forma outlook. Diagnostics pro forma organic growth was 11%, while adjusted operating margin expanded to 29.3% company-wide [#SEC-8K-2026-08-04].

Research note

Recommendation

—

Confidence

high

As of

2026-08-07

Base target

$121

p=50%

Bull target

$130

p=30%

Bear target

$100

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-print market reaction
Diagnostics growth and portfolio reshaping
The Q2 result showed stronger diagnostics demand, adjusted margin expansion, and a raised FY26 pro forma outlook.

BearKey bullets

China Immunodiagnostics represented approximately 6% of FY2025 revenue; divestiture execution and regulatory approval remain outstanding through the expected 2027 close [#SEC-8K-2026-08-04].
Life Sciences pro forma organic revenue declined 3% and segment adjusted margin fell to 31.1% from 31.6% [#SEC-8K-2026-08-04].
Q2 adjusted EPS benefited from approximately $0.11 of tariff-related refunds, creating a quality and repeatability risk [#SEC-8K-2026-08-04].

WatchKey bullets

Q2 2026 beat and raised FY26 outlook

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $121 (p=50%)

Target spread vs base: +7% / -17%

Scenario probabilities

Bull Target: $130 (p=30%)Base Target: $121 (p=50%)Bear Target: $100 (p=20%)

Commentary

Earnings-led news tone is moderately positive after the Q2 beat and raised outlook. A secondary market-data source reports a 6.694% post-earnings gain, but the window is unspecified and no verified post-print analyst revisions were identified. The deterministic prior turned positive with improving expected returns, while tariff-refund benefits, Life Sciences softness, and divestiture execution temper conviction.

As of 2026-08-07 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-print market reaction
Diagnostics growth and portfolio reshaping

Scenarios

Bull Target (Scenario probability)

$130 / p=30% prob

Base Target (Scenario probability)

$121 / p=50% prob

Bear Target (Scenario probability)

$100 / p=20% prob

Analysis 2026-08-07 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-08-04
Q2 2026 beat and raised FY26 outlook
Revvity reported Q2 revenue of $730 million, adjusted EPS of $1.41, 4% pro forma revenue growth, and 3% pro forma organic growth. Management described results as above expectations and raised FY26 pro forma revenue guidance to $2.83-$2.86 billion and adjusted EPS guidance to $5.30-$5.40 [#SEC-8K-2026-08-04].
Prob 95.00% • Move 5.00% • Priced-in 75.00%

Short-term Catalysts

Next few weeks

Post-print market reaction
2026-08-07
A secondary market-data page reports a 6.694% post-earnings stock-price increase, but the measurement window is unspecified. No verified post-print analyst target or estimate revision was identified, so follow-through remains uncertain.
Prob 60% • Move 3% • Priced-in 65%

Long-term Catalysts

Months to a year

Diagnostics growth and portfolio reshaping
2027-12-31
Diagnostics delivered 11% pro forma organic growth with adjusted operating margin of 30.4%, while the company entered a definitive agreement to divest China Immunodiagnostics, approximately 6% of FY2025 revenue, with closing expected by the end of 2027 subject to approvals [#SEC-8K-2026-08-04].
Prob 65% • Move 8% • Priced-in 40%

Risks

China Immunodiagnostics represented approximately 6% of FY2025 revenue; divestiture execution and regulatory approval remain outstanding through the expected 2027 close [#SEC-8K-2026-08-04].
Life Sciences pro forma organic revenue declined 3% and segment adjusted margin fell to 31.1% from 31.6% [#SEC-8K-2026-08-04].
Q2 adjusted EPS benefited from approximately $0.11 of tariff-related refunds, creating a quality and repeatability risk [#SEC-8K-2026-08-04].
The reported post-earnings price increase has no specified measurement window, and verified post-print analyst revisions remain unavailable.

Peers

Symbol	Summary
CRL	Closest supplied same-sector, similar-market-cap reference, though its CRO model differs from Revvity's tools and diagnostics portfolio.
ARWR	Higher-beta biotech reference for growth and optionality; business mix is materially different, so comparison is loose.
GILD	Large-cap, cash-generative biopharma benchmark for quality and valuation support, but substantially more mature than Revvity.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-07

Loading AI feed…

Symbol

Summary

CRL

Closest supplied same-sector, similar-market-cap reference, though its CRO model differs from Revvity's tools and diagnostics portfolio.

ARWR

Higher-beta biotech reference for growth and optionality; business mix is materially different, so comparison is loose.

GILD

Large-cap, cash-generative biopharma benchmark for quality and valuation support, but substantially more mature than Revvity.